BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$82.08B, compared with -$5.26M a year earlier. Trailing-twelve-month EBITDA was -$81.69B. Over 3 fiscal years it compounded at +29.2% a year.
Context
- EBITDA amounted to 17.8% of revenue in FY2025, down 5.0 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 20 analysts of $818.9M (+42.9%) for the fiscal year ending Dec 2026, a step up from the -11.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$82.08B-37020.7% QoQ
- Last fiscal yearDec 2025
- $572.94M-11.9% YoY
- LTMSep 2026
- -$81.69B-10676.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 572.94M USD
- Year-over-year change
- -11.9%
- 4-year CAGR
- +86.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 572.94M | -11.9% |
| FY2024 | 2024-12-31 | 650.53M | +112.1% |
| FY2023 | 2023-12-31 | 306.77M | +15.6% |
| FY2022 | 2022-12-31 | 265.36M | +459.4% |
| FY2021 | 2021-12-31 | 47.43M | — |
EBITDA vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10676.6% is the lowest of 11, against a peer median of +4.7%.
- EBITDA amounts to 8.0% of revenue for BMRN, versus a peer median of 30.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.86B USD | +4.3% | +3.1% | 37.4% | |
| LTM Jun 2026 | $1.15B USD | +773.6% | — | 24.0% | |
| LTM Sep 2026 | €259.93M EUR | +295.2% | — | 21.5% | |
| LTM Jun 2026 | $173.52M USD | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $39.48M USD | +82.4% | -1.9% | 10.7% | |
| LTM Sep 2026 | -$106.58M USD | -372.0% | — | 16.4% | |
| LTM Sep 2026 | -$473.54M USD | -208.3% | — | 49.3% | |
| LTM Mar 2026 | -$503.35M USD | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$611.26M USD | +5.0% | — | 85.7% | |
| LTM Jun 2026 | -$770.76M USD | +17.8% | — | 67.8% | |
| LTM Sep 2026 | -$81.69B USD | -10676.6% | +29.2% | 8.0% | |
| Peer median (excluding BMRN) | — | +4.7% | +0.6% | 30.7% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.